EU/3/17/1913:

Teicoplanin

Overview

On 23 August 2017, orphan designation (EU/3/17/1913) was granted by the European Commission to Neupharma S.r.l., Italy, for teicoplanin for the treatment of cystic fibrosis.

The sponsor’s address was updated in April 2021.

Key facts

Active substance
Teicoplanin
Medicine name
-
Intented use
Treatment of cystic fibrosis
Date of designation
23/08/2017
Orphan designation status
Positive
EU designation number
EU/3/17/1913

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Neupharma S.r.l.
Via Aldrovandi 6 
40026 Imola BO
Italy
E-mail: fabio.borella@neupharma.it
 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating